Skip to main content

Press releases | March 19, 2025

Fried Frank acted as counsel to Evercore as financial advisor to Optinose (NASDAQ:OPTN) in its $330 million sale to Paratek Pharmaceuticals. This acquisition expands Paratek’s commercial portfolio beyond its flagship antibiotic, NUZYRA® (omadacycline), and strengthens its position as a multi-product company focused on innovative specialty therapies for primary care providers and specialists.

The Fried Frank team was led by partner Roy Tannenbaum. 


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.